Salubris Biotherapeutics Announces New Pipeline Advancements and Appointment of Chief Medical Officer

– Lead Clinical Candidate, JK07, Demonstrates Favorable Safety and Further Promising Activity in Cohort 2 of Phase 1b Heart Failure with Reduced Ejection Fraction Study; Enrollment in Cohort 3 Now Ongoing – – Clinical Trial Application Submitted in Europe for Lead Oncology Program JK08, the first CTLA-4/IL-15 Antibody Fusion Protein, for the Treatment of Solid … [Read more…]

AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022

ENHERTU® (fam-trastuzumab deruxtecan-nxki) data will show the potential to improve survival for metastatic breast cancer patients and define a new segment of HER2-low disease Results from multiple trials further reinforce strength of industry-leading portfolio and pipeline, including novel combinations, across cancers with high unmet need WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca advances its ambition to redefine cancer care … [Read more…]

Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata

THRIVE-AA1 Study Meets Primary Endpoint for Scalp Hair Regrowth and Key Secondary Endpoints at Both Doses Statistically Significant Hair Regrowth Observed as Early as Eight Weeks CTP-543 Has Potential to be Best-in-Class for the Treatment of Alopecia Areata Topline Data from Second Phase 3 Trial, THRIVE-AA2, Expected Third Quarter of 2022 LEXINGTON, Mass.–(BUSINESS WIRE)–$CNCE #AlopeciaAreata—Concert … [Read more…]

Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran

– New Exploratory Findings from 18-Month Analysis of HELIOS-A Suggest that Treatment with Investigational Vutrisiran May Benefit Patients with Hereditary ATTR (hATTR) Amyloidosis and Cardiac Involvement – – Improvements in NT-proBNP and Echocardiographic Parameters Seen in Cardiac Subpopulation – – Reductions in Technetium Uptake Observed in Patients with High Grade Uptake at Baseline – CAMBRIDGE, … [Read more…]

Modra Pharmaceuticals to Present New Phase 2b Data at the 2022 ASCO General Annual Meeting on ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer

AMSTERDAM–(BUSINESS WIRE)–Modra Pharmaceuticals (“Modra”) today announced that the company will present new data from its Phase 2b trial evaluating ModraDoc006/r, a boosted oral taxane therapeutic versus the standard-of-care IV chemotherapy docetaxel, in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC) at the upcoming ASCO General Annual Meeting held from June 3 – 7, 2022 virtually and … [Read more…]

Three Day Virtual Pharmaceutical SOP Writing, Training and Compliance Course, July 25-26, 2022 –

DUBLIN–(BUSINESS WIRE)–The “SOP Writing, Training and Compliance in the Pharmaceutical Industry” training has been added to’s offering. In this course you will learn the keys to writing effective SOPs, the vital connection between the documentation and training spheres, and how to maximize this connection to improve the quality of both SOPs and training. Standard … [Read more…]

New Study Finds That Masimo PVi® May Be Useful in Helping ER Doctors Determine the Severity of Asthma Attacks in Pediatric Patients

Researchers Said Masimo PVi Can Be Used As a “Noninvasive, Rapid, and Objective Tool” for Helping Clinicians Predict Response to Treatment and Follow Up in Children with Obstructive Respiratory Disease NEUCHATEL, Switzerland–(BUSINESS WIRE)–Masimo (NASDAQ: MASI) today announced the findings of a retrospective study published in the American Journal of Emergency Medicine in which Dr. Gülsah … [Read more…]

Alcon to Acquire EYSUVIS Adding to Its Ophthalmic Eye Drop Portfolio

Expands ophthalmic eye drop portfolio leveraging market access expertise and newly created US ophthalmic eye drop sales force EYSUVIS complements Systane Preservative-Free by expanding treatment options for dry eye GENEVA–(BUSINESS WIRE)–Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has signed an agreement to acquire EYSUVIS® … [Read more…]

Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting

– In ECOSPOR lll, Seres’ lead therapeutic candidate incorporated itself rapidly and durably into the microbiome to prevent C. difficile infection recurrence – – Within one week of treatment, SER-109 was observed to diversify the microbiome and support the production of fatty acids that inhibit the growth of C. difficile – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Seres Therapeutics, … [Read more…]

Fractyl Health Presents New Mechanistic Data on Revita® DMR in Type 2 Diabetes 

Patients treated with Revita experienced a 0.8%-point reduction in HbA1c along with a 33% improvement in markers of insulin sensitivity three months after undergoing the procedure Markers of insulin production capacity in the pancreas also improved, with a 25% increase in insulin secretion rate and a 37% improvement in Disposition Index  LEXINGTON, Mass.–(BUSINESS WIRE)–Fractyl Health, … [Read more…]